A medical-device quality reviewer answers 2025 questions about Boston Scientific: endoscopy news, the Nalu Medical acquisition, ICD devices, nuclear medicine, and what spine surgery actually involves.

I review medical-device content for a living—regulatory claims, package statements, clinical training pieces. Boston Scientific materials cross my desk regularly, and the first thing I check is not whether a product sounds impressive. It is whether the claim can be verified against the current label. In this industry, that gets harder every year because the portfolio keeps moving.

Below are the questions I get from hospitals, clinicians, procurement teams, and patients in 2025. The answers are not press-release copy. They reflect what I actually look at when a Boston Scientific announcement lands in my review queue.

What Counts As Boston Scientific Endoscopy News in 2025?

If you follow headlines, Boston Scientific endoscopy news reads like a steady stream of product launches. The more useful interpretation is strategic: the company is moving away from the old story that endoscopy is about scopes and diagnosis, and toward a story about therapeutic procedures.

The clearest marker was the completion of the Apollo Endosurgery acquisition in early 2023, which added OverStitch—an endoscopic suturing platform—to the gastrointestinal portfolio. That device turned what used to be a surgical problem into something a gastroenterologist can approach through a scope. The same strategic thread runs through the EXALT single-use duodenoscope. For hospital reprocessing teams, single-use platforms solve a real and measurable problem: scope reprocessing failures can happen, and infection risk is not worth the old gamble.

To be fair, not all the news is about products. Much of the 2024 and 2025 conversation has centered on clinical data readouts presented at Digestive Disease Week—EUS-guided drainage, advanced stenting, and endoscopic bariatric procedures. The broader point is that the boundary between surgery and endoscopy keeps dissolving. Fifteen years ago, a patient would not have had these options. Now the conversation is about training, patient selection, and cost. That is a different kind of news.

Why Is Boston Scientific Acquiring Nalu Medical in 2025?

Boston Scientific's acquisition of Nalu Medical in 2025 is, on the surface, another neuromodulation deal. The more useful way to read it is as a response to why many patients avoid neurostimulation in the first place.

Conventional spinal cord stimulation requires an implantable pulse generator large enough to create a pocket under the skin. That generator has gotten smaller over the years, but Nalu designed its platform around a significantly smaller implantable pulse generator. That matters more than it sounds. I have reviewed device specifications side by side, and implant volume is often the quiet factor behind patient resistance. A smaller implant changes the procedural story: less tissue disruption, a smaller pocket, and a lower perceived barrier for someone who is already hesitant about an implanted device.

I cannot tell you that the deal will reduce costs or eliminate pain; those are clinical claims, which belong in trial data, not in acquisition press releases. What the acquisition signals is direction. Boston Scientific is treating less invasive neuromodulation as a growth category, and Nalu gives it a platform built around that exact premise.

What Is an ICD Device in 2025?

An ICD device—implantable cardioverter-defibrillator—is a battery-powered unit placed under the skin, usually below the collarbone. Leads monitor the heart and, if a dangerous ventricular arrhythmia develops, the device can deliver anti-tachycardia pacing or a defibrillation shock.

An ICD is not the same as a pacemaker, though some models perform both functions. A pacemaker mainly corrects a heart rate that is too slow. An ICD is there to stop a rhythm that can be lethal if it is not interrupted quickly.

Boston Scientific offers conventional transvenous ICDs and the S-ICD, a fully subcutaneous option that keeps the lead out of the heart. For younger patients, patients with difficult venous access, or anyone who will need decades of lead management, that distinction can be significant.

Device technology has improved even if public perception has not caught up. Many current ICDs are designed to be MRI-conditional, so imaging access is no longer automatically lost after implantation. Remote monitoring means the clinic can detect arrhythmia episodes or battery decline without waiting for the patient to feel symptoms. When I review claims about ICDs, I am less interested in the shock itself and more interested in battery longevity, infection prevention, and the follow-up infrastructure that supports the device after discharge.

Wait—What Does Boston Scientific Have to Do With Nuclear Medicine?

Not what most people assume. Boston Scientific does not sell PET scanners, CT scanners, gamma cameras, or radiopharmaceuticals. But it does have a product that pulls the company into nuclear medicine workflows: TheraSphere.

TheraSphere came to Boston Scientific through the BTG acquisition completed in 2019. It is made of tiny glass microspheres containing yttrium-90, a radioactive isotope. An interventional radiologist infuses the microspheres through a catheter into the hepatic artery, where they concentrate in liver tumors and deliver a high local dose of radiation. The treatment is called radioembolization or selective internal radiation therapy. It is not chemotherapy, and it is not external-beam radiation.

Here is the piece that surprises readers: nuclear medicine expertise is part of safe use. Before the yttrium-90 dose is given, the care team often needs to estimate lung shunt—how much of the radioactive material could escape to the lungs. That evaluation typically uses technetium-99m macroaggregated albumin and a nuclear scan. After administration, imaging may be used to confirm the distribution of the microspheres. So the connection is not about building imaging equipment. It is about offering a treatment that requires nuclear medicine expertise to be delivered safely.

Early in my career, I edited a summary describing TheraSphere as chemotherapy beads. A radiation safety officer corrected me quickly. That correction stuck: if terminology gets sloppy in patient-facing materials, clinical decisions can get sloppy too.

What Is Spine Surgery?

Spine surgery is an operation on the spine—vertebrae, discs, facet joints, nerves, or the spinal cord—to correct a structural problem. The most common types are microdiscectomy, laminectomy, spinal fusion, and artificial disc replacement. Most people search for the phrase because an MRI report mentioned a disc bulge or stenosis and a doctor used the word surgery.

The honest answer is that surgery is sometimes necessary and sometimes not. A herniated disc with clear nerve compression can be fixed surgically with strong outcomes. But a lot of chronic back pain does not come from a single compressed nerve, and removing the disc alone will not solve pain that has another source.

One increasingly recognized source is the vertebral endplate, and the pain it causes is often called vertebrogenic pain. Boston Scientific entered that space through the 2023 acquisition of Relievant Medsystems, whose Intracept procedure targets the basivertebral nerve. The company also sells spinal cord stimulation systems, generally used for persistent pain after previous back surgery or when other therapies have not worked.

This is why Boston Scientific keeps showing up in conversations about spine surgery even though it does not make rods, screws, or fusion cages. The line between surgical treatment, interventional pain care, and neuromodulation is thinner than it used to be. For patients asking whether surgery is the only path, that blurrier line is actually good news.

How Should Hospitals Read a Boston Scientific Acquisition or Product Announcement?

I understand why procurement teams skim an announcement for product names and revenue figures. After years of reviewing these materials, I read them differently. Three questions matter more than the press release.

First, regulatory status. Some acquisitions close before the product is approved or cleared in the United States. A launch announcement is not the same as an FDA-labeled indication, and I have rejected first drafts that could not tell the difference. Second, integration. It is not enough to own a technology; the company has to train clinicians, answer questions, and respond when something goes wrong. Third, language. If a communication says a device treats a condition, it must match the label. If it starts to suggest a cure or universal superiority—and yes, some early drafts do—it gets cut.

It took me about five years of this work to understand what I was actually reviewing. The product landscape keeps shifting: Nalu adds neuromodulation, endoscopy moves into surgical territory, and ICDs become MRI-conditional. The fundamentals do not change: honest labeling, solid training, and follow-up that continues after discharge. What has changed is the execution. That is the part worth watching.